GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-06-30 pm EDT
2.420 USD   -1.63%
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell Small Cap Comp Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 2000 Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 3000E Value Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Gritstone bio, Inc.
Gritstone bio, Inc. is a biotechnology company. The Company discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The Company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).

Number of employees : 193 people.
Sales per Business
20202021Delta
Immunotherapies for Cancer and Infectious Disease4.04100%48.21100% +1094.3%
USD in Million
Sales per region
20202021Delta
United States4.04100%48.21100% +1094.3%
USD in Million
Managers
Name Title Age Since
Andrew R. Allen, Dr. President, Chief Executive Officer & Director 54 2021
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President 41 2021
Karin Jooss, Dr. Head-Research & Development 56 2021
Erin E. Jones Chief Operating Officer 49 2021
George E. MacDougall Director-Investor Relations & Communications - 2021
Vijay Yabannavar, Dr. Chief Technical Development Officer & Executive VP 60 -
Matthew Hawryluk, Dr. Chief Business Officer & Executive Vice President 43 2015
Rahsaan W. Thompson Executive Vice President & General Counsel 50 2020
Stacy Lea Proctor Senior Vice President & Head-People - -
James Cho Chief Accounting Officer - 2021
Members of the board
Name Title Age Since
Elaine V. Jones, Dr. Chairman 66 2020
Richard A. Heyman, Dr. Vice Chairman 63 -
Steve Krognes Independent Director 52 2018
Shefali Agarwal, Dr. Independent Director 47 2021
Naiyer A. Rizvi, Dr. Independent Director - 2021
Clare Fisher Independent Director - 2022
Andrew R. Allen, Dr. President, Chief Executive Officer & Director 54 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 72,812,833 70,647,570 97.0% 0 0.0% 97.0%
Shareholders
NameEquities%
Redmile Group LLC 6,871,738 9.44%
Ecor1 Capital LLC 6,012,232 8.26%
Frazier Life Sciences Management LP 5,237,348 7.19%
Frazier Management LLC 4,667,242 6.41%
Versant Venture Management LLC 3,561,150 4.89%
Deep Track Capital LP 2,985,729 4.10%
The Vanguard Group, Inc. 2,692,367 3.70%
Clarus Ventures LLC 2,567,445 3.53%
Palo Alto Investors LP 2,330,504 3.20%
Casdin Capital LLC 1,850,373 2.54%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gritstone bio, Inc.